Responses
Clinical/translational cancer immunotherapy
Original research
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
Compose a Response to This Article
Other responses
No responses have been published for this article.